QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

VERA

QT68Vera Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
35.09
+0.08+0.23%
OverviewShort InterestFilings
VERAQT68Vera Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
35.09+0.23%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own-
Shs Outstand71.78M
Perf Week4.28%
Market Cap2.51BForward P/E-EPS next Y-3.72Insider Trans-0.08%Shs Float-Perf Month5.53%
Enterprise Value2.47BPEG0.14EPS next Q-1.60Inst Own-Short Float-Perf Quarter-15.18%
Income-370433789.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y-27.35%
Sales-P/B5.01EPS next Y38.97%ROA-59.34%Short Interest-Perf YTD-30.71%
Book/sh6.97P/C-EPS next 5Y-ROE-74.86%52W High56.05 -37.40%Perf Year65.91%
Cash/sh8.32P/FCF-EPS past 3/5Y-ROIC-66.50%52W Low19.07 84.01%Perf 3Y-
Dividend Est.-EV/EBITDA-6.94Sales past 3/5Y-Gross Margin0.00%Volatility3.27% 4.62%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-101.45%Oper. Margin0.00%ATR (14)2.11Perf 10Y-
Dividend Ex-Date-Quick Ratio13.64Sales Y/Y TTM-Profit Margin0.00%RSI (14)52.87Recom2.25
Dividend Gr. 3/5Y-Current Ratio13.64EPS Q/Q-108.64%SMA204.49%Beta1.35Target Price80.33
Payout0.00%Debt/Eq0.15Sales Q/Q-SMA50-3.76%Rel Volume1.33Prev Close35.01
Employees152LT Debt/Eq0.13EarningsAug 04SMA200-5.60%Avg Volume1.13MPrice35.09
IPO DateMay 14, 2021Option/ShortYes / YesEPS/Sales Surpr.-27.22% -Net Debt/EBITDA0.11Volume1,497,437Change0.23%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-02-26ReiteratedJefferiesBuy$6.00 → $60
Jun-02-26ReiteratedGoldman SachsBuy$95 → $90
May-15-26ReiteratedEvercore ISI$95 → $91
Mar-11-26UpgradeWolfe ResearchPeer Perform → Outperform
Dec-19-25ReiteratedGoldman SachsBuy$95
Dec-11-25ReiteratedWedbushNeutral$34 → $33
Dec-08-25ReiteratedEvercore ISI$75 → $97
Dec-05-25ReiteratedPivotal Research$73
Nov-28-25ReiteratedH.C. Wainwright$15 → $90
Aug-04-25DowngradeWolfe ResearchOutperform → Peer Perform
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A000
Gross Profit000
Selling, General and Administrative Excl. Other1004124
Research and Development21512678
Other Operating Expense000
Operating Income-315-167-102
Interest Expense884
Unusual Expense
———
Non-Operating Income (Expense)-23-23-10
Net Income Before Taxes-300-152-96
Income Taxes
000
Consolidated Net Income-300-152-96
Net Income From Continuing Operations-300-152-96
Net Income-300-152-96
EPS (Recurring)-4.66-2.75-2.25
EPS (Basic, Before Extraordinaries)-4.66-2.75-2.25
EPS (Diluted)-4.66-2.75-2.25
EBITDA-292-144-92
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding645543
Market Capitalization3,241——
Operating Lease Expense
———
Insider Trading Volume
$38.34$33.46$28.58$23.70$18.82● Close Price0.00M1.32M2.64M3.96M5.28MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Fordyce MarshallPRESIDENT AND CEOMay 12 '26Sale36.7418,500679,747216,744May 13 12:00 AM
Fordyce MarshallPRESIDENT AND CEOApr 14 '26Sale44.0522,9511,011,051235,244Apr 15 12:00 AM
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRMar 13 '26Option Exercise3.9420,00078,79275,754Mar 16 12:00 AM
Brenner RobertChief Medical OfficerFeb 23 '26Sale41.982,15190,30750,947Feb 25 12:00 AM
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRFeb 23 '26Sale41.983,117130,86464,722Feb 25 12:00 AM
Grant SeanCHIEF FINANCIAL OFFICERFeb 23 '26Sale41.984,949207,778114,181Feb 25 12:00 AM
Fordyce MarshallPRESIDENT AND CEOFeb 23 '26Sale41.9816,925710,578257,163Feb 25 12:00 AM
JOHNSON DAVID LEEChief Operating OfficerFeb 23 '26Sale41.982,579108,27645,727Feb 25 12:00 AM
Turner William D.Chief Regulatory OfficerFeb 23 '26Sale41.982,18791,81945,313Feb 25 12:00 AM
Skelton Laurence MatthewChief Commercial OfficerFeb 23 '26Sale41.981,58266,41964,218Feb 25 12:00 AM
Turner William D.Chief Regulatory OfficerDec 15 '25Option Exercise15.5320,000310,600245,000Dec 17 12:00 AM
Turner William D.Chief Regulatory OfficerDec 15 '25Sale50.0810,000500,76722,500Dec 17 12:00 AM
ENRIGHT PATRICK GDirectorDec 11 '25Buy42.505,882249,9855,882Dec 15 12:00 AM
Turner William D.Chief Regulatory OfficerDec 08 '25Option Exercise15.5320,000310,600255,000Dec 10 12:00 AM
Turner William D.Chief Regulatory OfficerDec 08 '25Sale45.3110,000453,05322,500Dec 10 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR